You are here : Home > IDMIT partner of the European consortium INDENEO in the framework of the Rare Disease Research Challenge Call

Live in the center | Highlight | Brain

IDMIT partner of the European consortium INDENEO in the framework of the Rare Disease Research Challenge Call



Following the Rare Disease Research Challenge Call launched by the European Joint Programme for Rare Disease and the Rare Disease Foundation, the European INDENEO consortium project has been selected to respond to the challenge targeting the development of a system for intranasal administration of biological drugs to newborns. 

Among the partners of this project, IDMIT brings its expertise in preclinical trials.
Published on 13 July 2022

Following the Rare Disease Research Challenge Call launched by the European Joint Programme for Rare Disease and the Rare Disease Foundation, the European INDENEO consortium project has been selected to respond to the challenge targeting the development of an intranasal delivery system of biological drugs to neonates.

INDENEO (INtraNasal Device for NEOnates) brings together an international consortium of four partners :

  • EVEON,, project leader, bringsits expertise in the development of delivery devices and its ability to deliver microdoses ;
  • Chiesi for its expertise in pharmaceutical development and  neonatology ;
  • Les Cliniques universitaires Saint Luc (Belgique) for its top level clinical expertise ;
  • IDMIT (CEA-Jacob) for its expertise in carrying out pre-clinical trials.

INDENEO will last 18 months with two main milestones: the design and development of a functional prototype, then the pre-clinical validation.

> More informations : press release


Top page